European Commission logo
English English
CORDIS - EU research results

Exploiting GLIOblastoma intractability to address European research TRAINing needs in translational brain tumour research, cancer systems medicine and integrative multi-omics

Project description

European training network in translational research of glioblastoma

Glioblastoma (GBM) is a very aggressive and lethal brain cancer with 85% of patients dying within two years. Currently, there is no effective therapy for GBM and new treatment options are urgently required. The Marie Skłodowska-Curie Actions-funded GLIOTRAIN project will focus on the development of a European research training network of 14 organisations from 8 countries to train 15 creative young researchers. The objective of GLIOTRAIN is to discover new therapeutic strategies for GBM treatment, using next-generation sequencing, systems medicine, and integrative multi-omics to understand the disease resistance mechanisms. The project network will prepare a new generation of scientists to address translational research and clinical care of the GBM.


Glioblastoma (GBM) is the most frequent, aggressive and lethal of all brain tumours. It has a universally fatal prognosis with 85% of patients dying within two years. New treatment options and effective precision medicine therapies are urgently required. This can only be achieved by focused multi-sectoral industry-academia collaborations in newly emerging, innovative research disciplines. GLIOTRAIN will exploit the intractability of GBM to address European applied biomedical research training needs. The ETN, which comprises 9 beneficiaries and 14 partner organisations from 8 countries, will train 15 innovative, creative and entrepreneurial ESRs. The research objective of GLIOTRAIN is to identify novel therapeutic strategies for application in GBM, while implementing state of the art next generation sequencing, systems medicine and integrative multi-omics to unravel disease resistance mechanisms. Research activities incorporate applied systems medicine, integrative multi-omics leveraging state of the art platform technologies, and translational cancer biology implementing the latest clinically relevant models. The consortium brings together leading European and international academics, clinicians, private sector and not-for-profit partners across GBM fields of tumour biology, multi-omics, drug development, clinical research, bioinformatics, computational modelling and systems biology. Thus, GLIOTRAIN will address currently unmet translational research and clinical needs in the GBM field by interrogating innovative therapeutic strategies and improving the mechanistic understanding of disease resistance. The GLIOTRAIN ETN addresses current needs in academia and the private sector for researchers that have been trained in an environment that spans translational research, medicine and computational biology, and that can navigate confidently between clinical, academic and private sector environments to progress applied research findings towards improved patient outcomes.


Net EU contribution
€ 1 062 698,40
2 Dublin

See on map

Ireland Northern and Western Border
Activity type
Higher or Secondary Education Establishments
Total cost
€ 1 062 698,40

Participants (8)

Partners (14)